The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Prefilled Syringes Market (4th Edition), 2017 - 2026

  • Lowest Price Guaranteed From USD 2,349

  • Published
    January 2017

  • Pages
    525

  • View Count
    3907

Example Insights

An updated edition is available at the following link

View 5th edition

  1. Currently, more than 100 drugs and vaccines are available in prefilled syringes across different therapeutic classes. Humira®, Enbrel®, Copaxone®, Lovenox®, Rebif® and Pegasys® are examples of blockbuster drugs that are being extensively administered via prefilled syringes. In addition, over 65 drugs in prefilled syringe format are in clinical development for the treatment of number of indications such as rheumatoid arthritis and multiple sclerosis.
  2. The rise of biologics has emerged as a major growth driver. Additionally, a number of biologics are getting off patent in the coming few years. Biosimilar developers will be competing for the same drug and, in such situations, use of prefilled syringes as a mode of administration can act as a key differentiator. The market’s evolution in the long-term will be fueled by pipeline drugs, technological advances and the rising adoption in developing markets. Moreover, integration of prefilled syringes with advanced delivery systems such as pen and autoinjectors will aid in gaining wider adoption.
  3. The development and launch of dual / multi-chambered syringes and prefilled diluent syringes has enabled easier and faster delivery of lyophilized drugs. Novel lubrication technologies such as TriboFilm Research’s TriboGlide® and Becton Dickinson’s XSi™ coating technologies have been introduced to overcome the problems associated with the use of silicone oil. Additionally, the design and availability of silicone-free and tungsten-free syringes is making them more suitable for use with sensitive drugs such as biologics.
  4. The current market is highly consolidated and is dominated by a handful of key manufacturers such as Becton Dickinson, Gerresheimer, SCHOTT, and Nuova Ompi. Other key players include West Pharmaceutical Services and Vetter Pharma; these players have already driven some novel devices and technologies in the market and are likely to foster more innovation.
  5. Many regional players have recently surfaced. Specifically in China, which has a large home consumer market, domestic players have an installed annual production capacity of as high as 150 million units; Shandong Weigao Group Medical Polymer Company, Shandong Zibo Minkang Pharmaceutical Packing, and Shandong Pharmaceutical Glass are well-known players. In Japan, Arte Corporation, Nipro Corporation, Taisei Kako and Terumo Corporation are known manufacturers of prefilled syringes; similarly, Roselabs Group, an India based manufacturer has invested heavily in this area.
  6. Aseptic filling of sterile drugs into prefilled syringes is one of the most crucial steps in pharmaceutical production. During the course of our study, we identified more than 45 contract manufacturing organizations, which provide fill and finish services for prefilled syringes. Majority (~70%) of the fill and finish service providers are based in North America and Europe. Prominent players in these regions include Biopharma Solutions, Catalent, Pfizer CentreOne, Rovi CM and Boehringer Ingelheim BioXcellence. Some well-known fill and finish service providers based in emerging markets include Cipla BioTec, DM Bio, Genovior Biotech and The Birgi Mefar Group.
  7. We anticipate the global prefilled syringe market to grow at an annualized rate of 3.9% between 2016 and 2026. The majority share of the prefilled syringes market is currently divided between North America (35%) and the EU (45%). We believe that the prefilled syringes markets in Asia, Latin America, the Middle East and Africa are likely to grow at faster rate than those of the more developed regions.

Overview

Injectable drug delivery systems have traversed a long way from conventional syringes with vials to prefilled syringes, autoinjectors, pen injectors and needle free systems. These modern devices have become preferred devices for parenteral administration of drugs. Specifically, the demand for prefilled syringes has been rising strongly over the past several years. A growing number of healthcare facilities are now adopting this format for delivering drugs. The popularity of prefilled syringes is not limited to healthcare settings; self-injecting patients looking for easier and safer methods also prefer using prefilled syringes for drug administration in home settings. The rise in parenteral drugs, especially biologics for the treatment of diseases and chronic conditions, such as multiple sclerosis and rheumatoid arthritis, has forced drug and packaging manufacturers to seek more sophisticated container closure and drug delivery systems. Responding to this increasing preference, pharmaceutical companies are now packaging a number of their injectable drugs and vaccines in prefilled syringe format. Over 100 injectable drug products are available in prefilled syringes and a rising number of pipeline drugs are targeted to be delivered by this method. 
The origins of prefilled syringes can be traced back to the early 1980s when Sanofi and Rhone Poulenc-Rorer (Sanofi-Aventis) introduced them as drug delivery devices for heparins in Europe. They have been around for more than three decades now and are used for administration of all major classes of therapeutics, including vaccines, anticoagulants, anti-arthritic drugs and anti-anemic drugs. Prefilled syringes have improved significantly over the years. Manufacturers have recently developed multi-chamber syringes for use with lyophilized drugs. Such syringes are also being integrated with advanced injection devices, such as autoinjectors and pen injectors. In addition, prefilled diluent syringes and flush syringes are already quite popular. With more than 60% of candidate drugs / therapies in the clinical pipeline being biologics that usually require parenteral administration, the adoption of prefilled syringes is anticipated to further increase in the mid-long term.
 
Scope of the Report

The ‘Prefilled Syringes Market (4th edition), 2017-2026’ report provides a comprehensive analysis of the current state of prefilled syringes market and the likely future evolution of these devices over the next decade. Starting with an overview on prefilled syringes, the report elaborates on the development and manufacturing of prefilled syringes. It also includes information on needlestick injuries and provides an overview of the safety laws and legislations related to prefilled syringes across the major markets in the world.

Some of the key objectives of the report were to enumerate the various prefilled syringe systems that are available in the market, identify the drugs that are available in such dosage forms and estimate their corresponding market potential across different geographical regions. Specifically, the report includes insights on:

  • The current state of the market with respect to key players, targeted disease indications and the therapeutic classes of drugs that are available in the form of prefilled syringes, including a brief overview of biologics and biosimilars that are considered to be one of the primary growth drivers of this market.
  • The key drugs that are available in prefilled syringes; this has been presented in the form of detailed case studies.
  • The regulatory landscape in different countries, including the guidelines related to the grant of a marketing authorization for drugs in prefilled syringes.
  • The candidates that are likely to be tried for delivery via prefilled syringes in the future. It is worth highlighting that the candidates were chosen based on various parameters, such as their current route of administration, targeted indication and dosage frequency.
  • The key prefilled syringe and component manufacturers based in different geographies.
  • Product competitiveness and supplier power (in the form of 2 X 2 matrices) across the growing landscape of glass and plastic prefilled syringes.
  • Specialty syringes, which include prefilled flush syringes, prefilled diluent systems and contrast agents in prefilled syringes.
  • The contract manufacturing organizations providing fill / finish services related to prefilled syringes.
  • Future growth opportunities that are likely to drive the market in the short and long terms.

The study also features a detailed analysis of the existing market size and the potential future growth opportunities of these drug delivery devices across different classes of therapeutics. The analysis includes volumetric (number of units of prefilled syringes) and financial (future market size) projections of the market’s evolution over the next ten years (2017-2026). We have provided insights on the regional evolution of the prefilled syringes market covering North America, Europe (UK, France, Italy, Spain, Germany and the rest of Europe), Latin America (Brazil, Mexico, Argentina and the rest of Latin America), Asia Pacific (Japan, China, India, South Korea and the rest of Asia Pacific), and the Middle East and Africa (Saudi Arabia, UAE, Africa and the rest of the Middle East). In addition, we have provided the likely evolution distributed by the type of material (glass and plastic), and nature of molecules (vaccines, biosynthetic insulins, synthetic pentasaccharides, monoclonal antibodies, small molecules). The forecast takes into account the impending price variations that are likely to emerge in the mid-long term as a result of growing adoption and increased competition. In order to account for the uncertainties associated with drug development and production, we have forecasted three different market scenarios, depicting conservative, base and optimistic tracks of the industry’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with experts in this field. These included contributions from Kevin Cancelliere and Tibor Hlobik (Marketing Directors, West Pharmaceutical Services), Kirti Maheshwari (Chief Technical Officer, Intas Pharmaceuticals), Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies), and Rondald Wheet (Chief Executive Officer, Revolutions Medical). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter 2  provides an executive summary of the insights captured in our research and offers a high level view on where the market for prefilled syringes is headed in the mid-long term.

Chapter 3  provides a general overview of prefilled syringes, including details on their origin, required components (barrel, lock adapter, lubricant, needle, needle shield, plunger rod / piston, plunger stopper and tip cap) and manufacturing material (glass and plastic) . The chapter outlines the various types of prefilled syringe systems that are available in the market and provides details on the companies that manufacture such products. It also includes a discussion on the technological advances that have taken place in the recent past.

Chapter 4  highlights the growing concerns associated with needlestick injuries and the various legislative steps that have been taken to prevent them. These include installing various safety features in modern versions of prefilled syringes. In addition, the chapter provides information on some of the safety systems, including both add-on devices and device integrated features, and the companies involved in developing and manufacturing such solutions.

Chapter 5  presents information on the regulatory environment related to the grant of marketing authorizations for combination products across different countries. It highlights the role of regulatory bodies in the approval of prefilled syringes in North America, Europe, Latin America, Asia Pacific and the Middle East.

Chapter 6  features a detailed discussion on the key growth drivers of the prefilled syringes market. It also describes the rise in the number of chronic diseases, the growing trend of self-injection, changing patient demographics, and the emergence of biologics / biosimilars.

Chapter 7  provides details of the various products available in the form of prefilled syringes, primarily focusing on injectable drugs and vaccines. The chapter includes case studies of some of the marketed drugs available as prefilled syringes, such as Humira®, Enbrel®, Copaxone®, Lovenox® and Abilify Maintena®. We have also captured details on the molecules that are under clinical development as prefilled syringes. The chapter features a grid analysis, representing the distribution of pipeline drugs across different therapeutic areas and different stages of clinical development. Additionally, the chapter outlines major therapeutic drug classes that are available as prefilled syringes. For each therapeutic class, we have identified the drugs that are already available in prefilled syringes, their estimated patent expiry dates and corresponding generics / biosimilars that are under development.

Chapter 8  presents a list of drug candidates (marketed / pipeline) that are likely to be tried for delivery via prefilled syringes in the future. This list is based on insights gathered on the respective routes of administration of these candidates, the nature of the indication they are prescribed for, dosage frequency and annual sales (in case of marketed drugs).

Chapter 9  provides detailed profiles of some of the key manufacturers of prefilled syringes based in different geographies. Each profile includes a brief overview of the company, its financial information, product portfolio, technology platforms, recent facility expansions and / or acquisitions, and a comprehensive future outlook. The companies that have been included in this section include Aguettant, Becton Dickinson, Gerresheimer, Nipro Corporation, Nuova Ompi, SCHOTT, Terumo Corporation, Unilife, Vetter Pharma, Weigao Group Pharmaceutical Packaging Products Company and West Pharmaceutical Services. In addition, we have included brief profiles of some of the key prefilled syringe manufacturers that are based in emerging markets. The chapter also presents 2 X 2 matrix representations, comparing product competitiveness and supplier power of both glass and plastic prefilled syringes.

Chapter 10  provides insights on the various prefilled syringe component manufacturers along with details of their respective product portfolios. The key players covered in this section include Aptar Stelmi, Datwyler and West Pharmaceutical Services.

Chapter 11  provides information on fill and finish activities and the processes and technologies associated with them. The chapter highlights the importance of aseptic fill and finish operations, and features a discussion on future trends in this segment. It also includes detailed profiles of the global players that are engaged in this segment of the industry.

Chapter 12  features information on specialty syringes, namely prefilled flush syringes, prefilled diluent systems and contrast agents that are supplied in prefilled syringes. For each type of specialty syringe, we have provided a brief overview and presented details such as the different products that are available in the market and their advantages.

Chapter 13  offers a comprehensive perspective on how the prefilled syringe market is likely to evolve over the next ten years. Based on data collected through secondary research and insights from primary research, we adopted a top-down approach in order to estimate the future size of the market, both in terms of volume (number of units) and value (in USD billion). We have projected the market’s evolution North America, Europe (UK, France, Italy, Spain, Germany and the rest of Europe), Latin America (Brazil, Mexico, Argentina and the rest of Latin America), Asia Pacific (Japan, China, India, South Korea and the rest of Asia Pacific), and the Middle East and Africa (Saudi Arabia, UAE, Africa and the rest of the Middle East). In addition, we have looked at the market’s evolution by the type of material (glass and plastic) used and the nature of the product contained within the syringe (vaccines, biosynthetic insulins, synthetic pentasaccharides, monoclonal antibodies, small molecules and others). The analysis presents insightful 2 X 2 matrices based on Market Share and Market Attractiveness derived from the current and likely future state of the market.

Chapter 14  presents a list of autoinjectors that utilize prefilled syringes as their primary containers. In this chapter, we have included profiles of manufacturers of such autoinjectors, featuring an overview of the company and respective product portfolios. The key players that have been covered in this section include Bespak, DALI Medical Devices, Elcam Medical, Nuance Owen Mumford, SHL Group, Union Medico and Ypsomed Delivery Systems.

Chapter 15  discusses the recent technological developments in this domain and their applications. The chapter provides details on the advances in design technology and manufacturing of prefilled syringes that have enabled pharmaceutical companies to market lyophilized drugs in dual / multi chambered systems. The chapter highlights the advances related to novel lubrication and sterilization technologies as well.

Chapter 16  provides a comprehensive SWOT analysis of the prefilled syringes market. The chapter presents strategic insights on major factors that have contributed to the growth of the market, while highlighting the weaknesses and threats that are likely to have an impact on its future.

Chapter 17  summarizes the overall report. In this chapter, we have provided a recap of the key takeaways and expressed our independent opinion, based on the research and analysis described in previous chapters, on how the market is likely to fare in the shot and long terms.

Chapter 18  is a collection of interview transcripts of our discussions with some of the key players in this industry. In this chapter, we have presented the details of our conversations with Kevin Cancelliere and Tibor Hlobik (Marketing Directors, West Pharmaceutical Services), Kirti Maheshwari (Chief Technical Officer, Intas Pharmaceuticals), Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies), and Rondald Wheet (Chief Executive Officer, Revolutions Medical).

Chapters 19 and 20  are appendices, which provide tabulated data of all the charts and the list of companies that are mentioned in the report.

Table of Contents

1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. Executive Summary
 
3. Introduction to Prefilled Syringes
3.1. Chapter Overview
3.2. History of Prefilled Syringes
3.3. Benefits of Prefilled Syringes over Traditional Injectable Devices
3.3.1. Benefits for Healthcare Professionals and End Users
3.3.2. Benefits for Manufacturers
3.3.3. Shift of Existing Formulations to Prefilled Syringes
3.4. Prefilled Syringes Components
3.5. Classification of Prefilled Syringes
3.5.1. Classification by Manufacturing Material of the Barrel
3.5.1.1. Glass: Historical Material of Choice
3.5.1.2. Limitations of Glass Prefilled Syringes
3.5.1.3. Addressing the Limitations of Glass Prefilled Syringes
3.5.1.4. Advantages of Plastic Prefilled Syringes
3.5.1.5. Slow Adoption of Plastic Prefilled Syringes
3.5.1.6. Factors Likely to Drive the Use of Plastic Prefilled Syringes
3.5.2. Classification by Number of Chambers in the Barrel
3.5.3. Classification by Type of Needle
3.5.4. Classification by Type of Processing
3.6. Critical Attributes of a Prefilled Syringe Design
3.7. Prefilled Syringe Systems Available in the Market
3.7.1. Glass Prefilled Syringes
3.7.2. Plastic Prefilled Syringes
3.8. Technological Developments in Prefilled Syringes
 
4. Needlestick Injuries
4.1. Chapter Overview
4.2. Incidence and Cost Burden
4.3. Government Legislations for Needlestick Injury Prevention
4.4. Safety Mechanisms used by Prefilled Syringe Manufacturers
4.4.1. Safety Systems: Add-On Devices
4.4.1.1. Becton Dickinson
4.4.1.2. Gerresheimer
4.4.1.3. West Pharmaceutical Services
4.4.1.4. Vetter Pharma
4.4.1.5. Tip-Top
4.4.1.6. Credence MedSystems
4.4.1.7. Schreiner MediPharm
4.4.2. Safety Systems: Integrated Devices
4.4.2.1. Unilife Corporation: Unifill Safety Syringes
4.4.2.2. MedPro Safety Products: Prefilled Safety Syringes
4.4.2.3. Taisei Kako: Fulject™ Safety Syringes
4.4.2.4. Globe Medical Tech: Vacuum Retract Safety Syringes
4.4.2.5. US Medical Instruments: SafeSnap
4.4.2.6. Revolutions Medical: RevVac™ Safety Syringes
4.4.2.7. MedicalChain International: MySafill iPPFSS
4.4.2.8. Owen Mumford: Unisafe™
 
5. Regulatory Landscape for Prefilled Syringes
5.1. Chapter Overview
5.2. Regulatory Approval of Combination Products in the US
5.2.1. Overview
5.2.2. Historical Background
5.2.3. Regulatory Bodies and their Role in Product Approval
5.2.4. Regulatory Approval Pathway for Prefilled Syringes
 
5.3. Regulatory Approval of Combination Products in Europe
5.3.1. Overview
5.3.2. Regulatory Bodies and their Role in Product Approval
5.3.3. Regulatory Approval for Prefilled Syringes
 
5.4. Regulatory Approval of Combination Products in Canada
5.4.1. Overview
5.4.2. Regulatory Bodies and their Role in Product Approval
5.4.3. Regulatory Approval of Prefilled Syringes
 
5.5. Regulatory Approval of Combination Products in Brazil
5.5.1. Overview
5.5.2. Regulatory Bodies and their Role in Product Approval
5.5.3. Regulatory Approval of Prefilled Syringes
 
5.6. Regulatory Approval of Combination Products in Mexico
5.6.1. Overview
5.6.2. Regulatory Bodies and their Role in Product Approval
5.6.3. Regulatory Approval of Prefilled Syringes
 
5.7. Regulatory Approval of Combination Products in Argentina
5.7.1. Overview
5.7.2. Regulatory Bodies and their Role in Product Approval
5.7.3. Regulatory Approval of Prefilled Syringes
 
5.8. Regulatory Approval of Combination Products in Australia
5.8.1. Overview
5.8.2. Regulatory Bodies and their Role in Product Approval
5.8.3. Regulatory Approval of Prefilled Syringes
 
5.9. Regulatory Approval of Combination Products in Japan
5.9.1. Overview
5.9.2. Regulatory Bodies and their Role in Product Approval
5.9.3. Regulatory Approval of Prefilled syringes
 
5.10. Regulatory Approval of Combination Products in China
5.10.1. Overview
5.10.2. Regulatory Bodies and their Role in Product Approval
5.10.3. Regulatory Approval of Prefilled syringes
 
5.11. Regulatory Approval of Combination Products in India
5.11.1. Overview
5.11.2. Regulatory Bodies and their Role in Product Approval
5.11.3. Regulatory Approval of Prefilled Syringes
 
5.12. Regulatory Approval of Combination Products in South Korea
5.12.1. Overview
5.12.2. Regulatory Bodies and their Role in Product Approval
5.12.3. Regulatory Approval of Prefilled Syringes
 
5.13. Regulatory Approval of Combination Products in Saudi Arabia
5.13.1. Overview
5.13.2. Regulatory Bodies and their Role in Product Approval
5.14. Regulatory Approval of Prefilled Syringes
 
5.15. Regulatory Approval of Combination Products in United Arab Emirates
5.15.1. Overview
5.15.2. Regulatory Bodies and their Role in Product Approval
5.15.3. Regulatory Approval of Prefilled Syringes
 
6. Growth Drivers
6.1. Chapter Overview
6.2. Increase in the Number of Self-Injecting Patients
6.3. Increase in Incidences of Chronic Diseases
6.4. Changing Patient Demographics
6.5. Growth of Biologics and Biosimilars
6.6. Changing Pharmaceutical Strategies
6.7. Increasing Focus on the Prevention of Needlestick Injuries
6.8. Convergence of Prefilled Syringes with Autoinjectors/Pen-Injectors
 
7. Products Available in Prefilled Syringes
7.1. Chapter Overview
7.2. Drugs Approved in Prefilled Syringes, 2013-2016
7.3. Drugs Approved in Prefilled Syringes: Therapeutic Area Analysis
7.4. Leading Drugs in Prefilled Syringes, 2016
7.5. Other Drugs Available in Prefilled Syringes, 2016
 
7.6. Case Studies
7.6.1. HUMIRA (Adalimumab), AbbVie / Eisai
7.6.1.1. Indications and Dosage Forms
7.6.1.2. Shift from Vials to Syringes
7.6.2. Enbrel (Etanercept), Amgen / Pfizer / Takeda
7.6.2.1. Indications and Dosage Forms
7.6.2.2. Shift from Vials to Syringes
7.6.3. Copaxone (Glatiramer Acetate), Teva Pharmaceuticals
7.6.3.1. Indications and Dosage Forms
7.6.3.2. Shift from Vials to Syringes
7.6.4. Lovenox / Clexane (Enoxaparin sodium), Sanofi / GL Pharma / Italfarmaco
7.6.4.1. Indications and Dosage Forms
7.6.4.2. Shift from Vials to Prefilled Syringes
7.6.5. Abilify Maintena (Aripiprazole Controlled Release), Otsuka Pharmaceutical / Lundbeck
7.6.5.1. Indications and Dosage Forms
7.6.5.2. Shift from Vials to Syringes
 
7.7. Pipeline Drugs in Prefilled Syringes
7.8. Pipeline Drugs: Therapeutic Area Analysis
 
7.9. Drugs Available by Therapeutic Classes
7.9.1. Anti-Rheumatics
7.9.1.1. Approved Injectables
7.9.1.2. Biosimilars
7.9.2. Multiple Sclerosis Drugs
7.9.2.1. Approved Injectables
7.9.2.2. Biosimilars
7.9.3. Antivirals
7.9.3.1. Approved Injectables
7.9.3.2. Biosimilars
7.9.4. Anticoagulants
7.9.4.1. Approved Injectables
7.9.4.2. Biosimilars / Generics
7.9.5. Vaccines
7.9.6. Diabetes Drugs
7.9.6.1. Insulin Market
7.9.6.2. Approved Injectables
7.9.6.3. Biosimilars
 
8. Likely Candidates for Prefilled Syringes
8.1. Chapter Overview
8.2. Marketed Molecules
8.2.1. Marketed Molecules: Likely Candidates for Prefilled Syringes
8.3. Pipeline Molecules
8.3.1. Pipeline Molecules: Most Likely Candidates for Prefilled Syringes
8.3.2. Pipeline Molecules: Likely Candidates for Prefilled Syringes
8.3.3. Pipeline Molecules: Less Likely Candidates for Prefilled Syringes
8.4. Vaccines: Likely Candidates for Prefilled Syringes
 
9. Manufacturers of Prefilled Syringes
9.1. Chapter Overview
9.2. Key Prefilled Syringe Manufacturers Based in North America
9.2.1. Becton Dickinson
9.2.1.1. Company Overview
9.2.1.2. Financial Performance
9.2.1.3. Glass Prefilled Systems
9.2.1.3.1. BD Hypak™ Prefilled Syringe
9.2.1.3.2. Luer Products
9.2.1.3.3. Staked Needle Products
9.2.1.3.4. BD Neopak™ Prefilled Syringe
9.2.1.4. Plastic Prefilled Systems
9.2.1.4.1. BD Sterifill™ Syringe Systems
9.2.1.5. Other Prefilled Delivery Systems
9.2.1.5.1. BD Uniject™
9.2.1.5.2. BD Soluvia™
9.2.1.6. BD Prefilled Technology Solutions
9.2.1.7. Recent Developments
9.2.1.7.1. Deals and Agreements
9.2.1.7.2. Expansions
9.2.1.8. Future Outlook
 
9.2.2. Unilife Corporation
9.2.2.1. Company Overview
9.2.2.2. Financial Performance
9.2.2.3. Glass Prefilled Syringe
9.2.2.3.1. Unifill Syringes
9.2.2.3.2. EZMix™ Syringes
9.2.2.4. Wearable Injector Platform
9.2.2.5. Ocular Delivery Systems
9.2.2.6. Novel Delivery Systems
9.2.2.7. Recent Developments
9.2.2.7.1. Deals and Agreements
9.2.2.7.1.1. Partnership with Amgen
9.2.2.7.1.2. Partnership with MedImmune
9.2.2.7.1.3. Partnership with AbbVie
9.2.2.7.1.4. Partnership with Global Pharma Company
9.2.2.7.1.5. Partnership with Novartis
9.2.2.7.1.6. Partnership with Hikma
9.2.2.7.1.7. Partnership with Sanofi
9.2.2.7.1.8. Partnership with Biodel
9.2.2.7.2. Expansion
9.2.2.7.3. Fundings
9.2.2.8. Future Outlook
 
9.2.3. West Pharmaceutical Services
9.2.3.1. Company Overview
9.2.3.2. Financial Performance
9.2.3.3. Plastic Prefilled Systems
9.2.3.3.1. Daikyo Crystal Zenith RU Prefilled Syringe
9.2.3.4. Drug Reconstitution Systems
9.2.3.5. Prefilled Technology Solutions
9.2.3.6. Recent Developments
9.2.3.6.1. Growth of CZ Syringes
9.2.3.6.2. Launch of NovaPure Plunger for Higher Volume Injections
9.2.3.6.3. Growth in Pharma Emerging Markets (Brazil, China and India)
9.2.3.6.4. Manufacturing Expansion
9.2.3.6.5. Development Pipeline
9.2.3.7. Future Outlook
 
9.3. Key Prefilled Syringe Manufacturers Based in Europe
9.3.1. Aguettant
9.3.1.1. Company Overview
9.3.1.2. Aguettant Prefilled Syringes
9.3.1.3. Aguettant Self-Injector Pen
9.3.1.4. Recent Developments
9.3.1.5. Future Outlook
 
9.3.2. Gerresheimer
9.3.2.1. Company Overview
9.3.2.2. Financial Performance
9.3.2.3. Glass Prefilled Systems
9.3.2.3.1. Gx Glass Syringes
9.3.2.4. Plastic Prefilled Systems
9.3.2.4.1. ClearJect Prefilled Syringes
9.3.2.4.2. Gx RTF Clearject Needle Syringe
9.3.2.5. Self-Injection Devices
9.3.2.6. Prefilled Technology Solutions
9.3.2.7. Recent Developments
9.3.2.7.1. Expansion of Product Portfolio
9.3.2.7.2. Expansion of Manufacturing Capacity for RTF syringes
9.3.2.7.3. Expansion of Capacity of Medical Plastic Systems
9.3.2.7.4. Growth in Emerging Economies
9.3.2.8. Future Outlook
 
9.3.3. Nuova Ompi
9.3.3.1. Company Overview
9.3.3.2. Financial Performance
9.3.3.3. Glass Prefilled Systems
9.3.3.3.1. EZ-Fill Syringes
9.3.3.4. Recent Developments
9.3.3.4.1. New Corporate Branding
9.3.3.4.2. Capacity Expansion across the Glass Divisions
9.3.3.4.3. Twist-Off Closure System for Prefilled Syringes
 
9.3.4. SCHOTT
9.3.4.1. Company Overview
9.3.4.2. Financial Performance
9.3.4.3. Glass Prefilled Syringes
9.3.4.3.1. syriQ (Previously Forma 3s) Glass Syringes
9.3.4.3.2. syriQ™ InJentle Syringes
9.3.4.4. Plastic Prefilled Syringes
9.3.4.4.1. TopPac Polymer Syringes
9.3.4.5. Recent Developments
9.3.4.5.1. TopPac Syringe System for Sensitive Drugs
9.3.4.5.2. TopPac Syringe System for Highly Viscous Drugs
9.3.4.5.3. TopPac 20 ml Syringe System for Infusion Therapy
9.3.4.5.4. Rebranding the Glass Prefilled Syringes
9.3.4.5.5. New Closure Systems for Plastic / Glass Prefilled System
9.3.4.5.6. Growth in the Pharma Emerging Markets (Brazil, China, India, Indonesia and Russia)
9.3.4.5.7. Expansion of Production Facilities in the US and EU
9.3.4.6. Future Outlook
 
9.3.5. Vetter Pharma
9.3.5.1. Company Overview
9.3.5.2. Lyo-Ject Glass Prefilled Syringe
9.3.5.3. Vetter-Ject
9.3.5.4. Recent Developments
9.3.5.4.1. Capacity Expansion
9.3.5.4.2. Collaboration with West Pharmaceutical Services
9.3.5.5. Future Outlook
 
9.4. Key Prefilled Syringes Manufacturers Based in Asia Pacific
9.4.1. Nipro Corporation (Acquired MGlas)
9.4.1.1. Company Overview
9.4.1.2. Financial Performance
9.4.1.3. Glass Prefilled Systems
9.4.1.4. Plastic Prefilled Systems
9.4.1.5. Recent Developments
9.4.1.6. Future Outlook
 
9.4.2. Weigao Group Pharmaceutical Packaging Products Company
9.4.2.1. Company Overview
9.4.2.2. Financial Performance
9.4.2.3. WeGo Glass Prefilled Syringe
9.4.2.4. Future Outlook
 
9.4.3. Terumo Corporation
9.4.3.1. Company Overview
9.4.3.2. Financial Performance
9.4.3.3. PLAJEX™: Plastic Prefilled Syringe
9.4.3.4. Safety Devices: Add-On Devices
9.4.3.5. Future Outlook
 
9.5. Other Manufacturers
9.5.1. Arte Corporation
9.5.2. J.O. Pharma (Subsidiary of Otsuka Holdings)
9.5.3. Roselabs Group
9.5.4. Shandong Zibo Minkang Pharmaceutical packing
9.5.5. Shandong Pharmaceutical Glass
9.5.6. Taisei Kako
9.5.7. Yangzhong Wealth Metal
9.5.8. Youlyy Industrial
 
9.6. Mapping the Competitive Landscape
 
10. Prefilled Syringe Component Manufacturers
10.1. Chapter Overview
 
10.2. West Pharmaceutical Services
10.2.1. Overview
10.2.2. Financial Performance
10.2.3. Prefilled Syringe Components
10.2.3.1. Plungers
10.2.3.2. Needle Shields and Tip Caps
10.2.3.3. Backstops
10.2.4. Manufacturing Facilities
 
10.3. Datwyler
10.3.1. Overview
10.3.2. Financial Performance
10.3.3. Prefilled Syringe Components
10.3.3.1. Plungers
10.3.3.2. Needle Shields and Tip Caps
10.3.4. Manufacturing of Prefilled Syringe Components
 
10.4. Aptar Stelmi
10.4.1. Overview
10.4.2. Financial Performance
10.4.3. Prefilled Syringe Components
10.4.3.1. Plungers
10.4.3.2. Needle Shields
10.4.3.3. Tip Caps
10.4.3.4. Stoppers
 
11. Fill-Finish Service Providers for Prefilled Syringes
11.1. Chapter Overview
11.2. Fill-Finish Processing of Prefilled Syringes
11.2.1. Steps Involved in Fill-Finish Process
11.2.2. Methods of Filling and Stoppering of Prefilled Syringes
11.2.3. Prefilled Syringe Filling Technologies
11.3. Outsourcing of Fill-Finish Operations
11.4. Growth Considerations
 
11.5. Fill-Finish Service Providers
11.5.1. Key Fill-Finish Service Provider(s): North America
11.5.1.1. BioPharma Solutions
11.5.1.2. Catalent
11.5.1.3. Pfizer CentreOne
 
11.5.2. Key Fill-Finish Service Provider(s): Latin America
11.5.2.1. PiSA Farmaceutica
 
11.5.3. Key Fill-Finish Service Provider(s): Europe
11.5.3.1. Boehringer Ingelheim BioXcellence
11.5.3.2. ROVI CM
 
11.5.4. Key Fill-Finish Service Provider(s): Asia Pacific
11.5.4.1. Cipla BioTec
11.5.4.2. DM Bio
11.5.4.3. Genovior Biotech
 
11.5.5. Key Fill-Finish Service Provider(s): Middle East
11.5.5.1. The Birgi Mefar Group
 
12. Specialty Prefilled Syringes
12.1. Chapter Overview
 
12.2. Prefilled Flush Syringes
12.2.1. Overview
12.2.2. Prefilled Flush Syringes Available in the Market
12.2.3. Advantages of Prefilled Flush Syringes
 
12.3. Prefilled Diluent Syringes
12.3.1. Overview
12.3.2. Lyophilized Drugs Available in Prefilled Diluent System
12.3.3. Advantages of Prefilled Diluent Syringe Systems
 
12.4. Contrast Agent Prefilled Syringes
12.4.1. Overview
12.4.2. Contrast Agents Available in Prefilled Syringes
12.4.3. Advantages of Using Prefilled Syringe for Contrast Agents
 
13. Global Prefilled Syringes Market Forecast, 2016-2026
13.1. Chapter Overview
13.2. Scope and Methodology
 
13.3. Global Market Size and Forecast
13.3.1. Prefilled Syringes for Vaccines
13.3.2. Prefilled Syringes for Drugs
13.3.2.1. Prefilled Syringes for Anticoagulants
13.3.2.2. Prefilled Syringes for Diabetes Drugs
13.3.2.3. Prefilled Syringes for Multiple Sclerosis Drugs
13.3.2.4. Prefilled Syringes for Anti-Arthritic Drugs
13.3.2.5. Prefilled Syringes for Anti-Anemic Drugs
13.3.2.6. Prefilled Syringes for Other Drug Classes
13.3.3. Specialty Prefilled Syringes
13.3.4. Overall Global Market Size
 
13.4. Prefilled Syringe Market Forecast by Regions
13.4.1. North America Prefilled Syringes Market
13.4.2. EU Prefilled Syringes Market
13.4.3. Asia Pacific Prefilled Syringes Market
13.4.4. Latin America Prefilled Syringes Market
13.4.5. Middle East and Africa Prefilled Syringes Market
13.4.6. Prefilled Syringes Market Attractiveness Analysis by Region
 
13.5. Prefilled Syringes Market Forecast by Type of Material
 
13.6. Prefilled Syringes Market Forecast by Nature of Molecule
13.6.1. Prefilled Syringes Market Attractiveness Analysis by Nature of Molecule
 
14. Case Study: Autoinjectors
14.1. Chapter Overview
14.2. Autoinjectors: Market Overview
 
14.3. Key Players
14.3.1. Bespak
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.2.1. Autoinjectors
14.3.1.2.1.1. Syrina™
14.3.1.2.1.2. ASI Autoinjector™
14.3.1.2.1.3. OTS Autoinjector™
 
14.3.2. DALI Medical Devices
14.3.2.1. Company Overview
14.3.2.2. Product Portfolio
14.3.2.2.1. Autoinjectors
14.3.2.2.1.1. SAN-L
14.3.2.2.1.2. SAN-P
14.3.2.2.1.3. SAN-DV
14.3.2.2.1.4. SAN-DV Pro
 
14.3.3. Elcam Medical (E3D Elcam Drug Delivery Devices)
14.3.3.1. Company Overview
14.3.3.2. Product Portfolio
14.3.3.2.1. Autoinjectors
14.3.3.2.2. Flexi-Q Disposable Autoinjector
14.3.3.2.2.1. Flexi-Q PFS
14.3.3.2.2.2. Flexi-Q HV
14.3.3.2.2.3. Flexi -Q DV
14.3.3.2.3. Flexi-Q Reusable Autoinjectors
14.3.3.2.3.1. Flexi-Q mMU
14.3.3.2.3.2. Flexi-Q eMU
 
14.3.4. Nuance Designs
14.3.4.1. Company Overview
14.3.4.2. Product Portfolio
14.3.4.2.1. Fusion™ Autoinjector
14.3.4.2.2. Quantum™ Autoinjector
 
14.3.5. Owen Mumford
14.3.5.1. Company Overview
14.3.5.2. Product Portfolio
14.3.5.2.1. Autoinjectors
14.3.5.2.1.1. Autoject Micro
14.3.5.2.1.2. Autoject 2
14.3.5.2.1.3. Autoject Mini
14.3.5.2.1.4. Autoject Uni
14.3.5.2.1.5. Autoject Multi
14.3.5.2.1.6. Autoject Flex
 
14.3.6. Scandinavian Health Limited (SHL) Group
14.3.6.1. Company Overview
14.3.6.2. Product Portfolio
14.3.6.2.1. Two-Step Disposable Autoinjectors
14.3.6.2.1.1. Amber (Pushclick Technology)
14.3.6.2.1.2. Molly
14.3.6.2.1.3. Molly RNS
14.3.6.2.1.4. Molly 2.25
14.3.6.2.1.5. Molly C
14.3.6.2.1.6. NAISA (Negasai™ Spring Technology)
14.3.6.2.2. Three-Step Disposable Autoinjectors
14.3.6.2.2.1. DAI
14.3.6.2.2.2. DAI-RNS
14.3.6.2.2.3. DAI-R
14.3.6.2.2.4. SDI-MIX+NIT™ (Needle Isolation Technology and Twist and Mix   Mechanism)
14.3.6.2.2.5. VSDI-MIX™
14.3.6.2.2.6. PSDI
14.3.6.2.3. PPI Injector (Rotaject Pressure Release Technology)
 
14.3.7. Union Medico
14.3.7.1. Company Overview
14.3.7.2. Product Portfolio
14.3.7.2.1. 45? Autoinjector
14.3.7.2.1.1. 45?/S Autoinjector
14.3.7.2.1.2. 45?/M Autoinjector
14.3.7.2.1.3. 45?/R Autoinjector
14.3.7.2.2. 90? Autoinjector
14.3.7.2.2.1. 90?/S Autoinjector
14.3.7.2.2.2. 90?/ M Autoinjector
14.3.7.2.2.3. 90?/ XL Autoinjector
14.3.7.2.2.4. SuperGrip™ Autoinjector
14.3.7.2.2.5. Exclusive™ Autoinjector
 
14.3.8. Ypsomed Delivery Systems
14.3.8.1. Company Overview
14.3.8.2. Product Portfolio
14.3.8.2.1. Pen Injectors
14.3.8.2.2. Autoinjectors
14.3.8.2.2.1. YpsoMate and YpsoMate 2.25
14.3.8.2.2.2. VarioJect™
14.3.8.2.2.3. YpsoMate Smart
 
15. Recent Developments and Applications of Prefilled Syringes
15.1. Chapter Overview
15.2. Prefilled Syringes for Lyophilized Drugs
15.2.1. Prefilled Diluent Syringes
15.2.2. Prefilled Dual / Multi-Chamber Syringes
15.2.2.1. Lyophilized Drugs Available in Dual / Multi-Chamber Prefilled Syringe
15.2.2.2. Prefilled Dual-Chambered Pen Injectors for Lyophilized Drugs
15.3. Multilayer Plastic Prefilled Syringes with Oxygen Barrier
15.4. Novel Lubrication Technology for Prefilled Syringes
15.5. Advancement in Terminal Sterilization of Prefilled Syringes
15.5.1. Noxilizer’s Nitrogen Dioxide Sterilization Technology
 
16. SWOT Analysis
16.1. Chapter Overview
16.2. Strengths
16.3. Weaknesses
16.4. Opportunities
16.5. Threats
 
17. Conclusion
17.1. Prefilled Syringes have Emerged as the Preferred Administration Device for Parenteral Drugs
17.2. Plastic Syringes are Anticipated to Grow at Faster Rate than Glass Syringes
17.3. Emergence of Biologics, Technological Advances and Many Other Factors will Sustain the Growth
17.4. Although the Market is Consolidated, New Entrants with Innovative Technologies are expected to Drive Future Evolution
17.5. CMOs are an Integral Part of the Value Chain, Providing Aseptic Fill / Finish Services
17.6. The Prefilled Syringes Market is Poised to Grow at a Moderate Pace over the Coming Decade
17.7. Concluding Remarks
 
18. Interview Transcripts
18.1. Chapter Overview
18.2. Kirti Maheshwari, Chief Technical Officer, Intas Pharmaceuticals
18.3. Kevin Cancelliere and Tibor Hlobik, Marketing Directors, West Pharmaceutical Services
18.4. Rondald Wheet, Chief Executive Officer, Revolutions Medical
18.5. Matthew Young, Founder and Chief Technology Officer, Oval Medical Technologies
 
19. Appendix 1: Tabulated Data
 
20. Appendix 2: List of Companies

List of Figures

Figure 2.1  Prefilled Syringes Market Evolution: 2016, 2021, and 2026 (Number of Units, Million)
Figure 2.2  Prefilled Syringes Market Landscape, 2016-2026: Geographic Trends
Figure 2.3  Prefilled Syringes Market Attractiveness Analysis by Region
Figure 2.4  Prefilled Syringes Market Attractiveness Analysis by Nature of Molecule
Figure 3.1  Glass Prefilled Syringes: Advantages and Disadvantages
Figure 3.2  Properties of Cyclic Olefin Copolymer and Cyclo Olefin Polymer
Figure 3.3  Plastic Prefilled Syringes: Advantages and Disadvantages
Figure 3.4  Critical Design Parameters of Prefilled Syringes
Figure 3.5  Prefilled Syringes: Market Landscape by Manufacturers
Figure 3.6  Technological Evolution of Prefilled Syringes
Figure 4.1  Worldwide Evolution in Healthcare Safety Legislation
Figure 5.1  Global Regulations Related to Prefilled Syringes
Figure 5.2  Approval Pathway for Combination Products in the US
Figure 5.3  Approval Pathway for Combination Products in Canada
Figure 5.4  Approval Pathway for Combination Products in China
Figure 6.1  Global Prevalence of Diabetes: Distribution by Countries, 2015 (Million, %)
Figure 6.2  Numbers of Biologics Approved by the USFDA, 2009-2016
Figure 6.3  Top Selling Biologics: Estimated Patent Expiry
Figure 7.1  Approved Drugs: Therapeutic Area Analysis (2013-2016)
Figure 7.2  Sales of Leading Drugs Available in Prefilled Syringes, 2016 (USD Million)
Figure 7.3  HUMIRA®: Approval Timeline (US, EU and Japan)
Figure 7.4  HUMIRA®: Approval Timeline for Various Dosage Forms (US and EU)
Figure 7.5  HUMIRA®: Annual Sales, 2003-Q3 2016 (USD Million)
Figure 7.6  Enbrel®: Approval Timeline (US and EU)
Figure 7.7  Enbrel®: Approval Timeline for Various Dosage Forms (US and EU)
Figure 7.8  Enbrel®: Annual Sales in the US and Canada, 2002-2015 (USD Million)
Figure 7.9  Enbrel®: Annual Sales outside US and Canada, 2010-2015 (USD Million)
Figure 7.10 Copaxone ®: Annual Sales, 2001-Q3 2016 (USD Million)
Figure 7.11  Copaxone ®: Distribution by Vials and Prefilled Syringes, 2000-2008 (Million Units)
Figure 7.12  Lovenox®: Approval Timeline (US)
Figure 7.13  Lovenox®: Global Annual Sales, 2009- Q3 2016 (EUR Million)
Figure 7.14  Abilify Maintena®: Approval Timeline (US, Canada, Europe, Japan)
Figure 7.15  Pipeline Drugs: Therapeutic Area Analysis
Figure 7.16  Number of Approved / Pipeline Biosimilars of Anti-Rheumatics
Figure 7.17  Number of Approved / Pipeline Biosimilars of Multiple Sclerosis Drugs
Figure 7.18  Number of Approved / Pipeline Biosimilars of Antivirals
Figure 7.19  Number of Approved / Pipeline Biosimilars and Generics of Anticoagulants
Figure 7.20  Number of Approved / Pipeline Biosimilars of Diabetes Drugs
Figure 8.1  Marketed Molecules: Parameters and Scoring Criteria
Figure 8.2  Pipeline Molecules: Parameters and Scoring Criteria
Figure 9.1  BD Medical: Annual Revenues, 2011-2016 (USD Billion)
Figure 9.2  BD Medical: Revenue Distribution by Sub-Segments, 2016 (USD Billion)
Figure 9.3  Unilife Corporation: Annual Revenues, FY 2011/12-2015/16 (USD Million)
Figure 9.4  West Pharmaceutical Services: Annual Revenues, 2011-Q3 2016 (USD Million)
Figure 9.5  West Pharmaceutical Services: Revenue Distribution by Business Segments, 2015 (USD Million)
Figure 9.6  West Pharmaceutical Services: Annual Revenues of Delivery Systems Segment, 2011-2015 (USD Million)
Figure 9.7  West Pharmaceutical Services: Annual Revenues in the US and Overseas, 2011-2015 (USD Million)
Figure 9.8  West Pharmaceutical Services: Revenue Distribution by Region, 2015 (USD Million)
Figure 9.9  Gerresheimer: Annual Revenues, 2011-Q3 2016 (EUR Million)
Figure 9.10  Gerresheimer: Revenue Distribution by Business Divisions, 2015 (EUR Million)
Figure 9.11  Gerresheimer: Revenue Distribution by Region, 2011- 2015 (EUR Million)
Figure 9.12  SCHOTT: Annual Revenues, FY 2012/13-FY 2014/15 (EUR Million)
Figure 9.13  SCHOTT: Revenue Distribution by Business Divisions, FY 2014/15 (EUR Million)
Figure 9.14  SCHOTT: Revenue Distribution by Region, FY 2014/15 (EUR Million)
Figure 9.15  Nipro Corporation: Annual Revenues, 2011/12-2015/16 (YEN Billion)
Figure 9.16  Nipro Corporation: Revenue Distribution by Business Divisions, 2015/16 (YEN Billion)
Figure 9.17  Nipro Corporation: Revenue Distribution by Region, 2015/16 (YEN Billion)
Figure 9.18  Nipro Corporation: Revenue Distribution by Region, 2011/12-2015/16 (YEN Billion)
Figure 9.19  Weigao: Annual Revenues of Prefilled Syringes, 2011-H1 2016 (RMB Million)
Figure 9.20  Weigao: Revenue Distribution by Product Category, 2015 (RMB Million)
Figure 9.21  Terumo Corporation: Annual Revenues, FY 2011-H1 2016 (YEN Billion)
Figure 9.22  Terumo Corporation: Revenue Distribution by Business Divisions, FY 2015/16 (YEN Billion)
Figure 9.23  Terumo Corporation: Revenue Distribution by Region, FY 2015/16 (YEN Billion)
Figure 9.24  Glass Prefilled Syringes: Product Landscape Analysis
Figure 9.25 Polymer Prefilled Syringes: Product Landscape Analysis
Figure 10.1  Datwyler Group: Annual Revenues, 2011-H1 2016 (CHF Million)
Figure 10.2  Datwyler Group: Revenue Distribution by Business Divisions, 2015 (CHF Million)
Figure 10.3  Aptar Stelmi: Annual Revenues, 2013-2015 (USD Million)
Figure 11.1  Prefilled Syringes: Fill-Finish Process
Figure 13.1  Prefilled Syringes Price Curve, 2016-2026 (USD per unit)
Figure 13.2  Prefilled Syringes Market for Vaccines, 2016-2026: Base Scenario (Million Units)
Figure 13.3  Prefilled Syringes Market for Vaccines, 2016-2026: Base Scenario (USD Million)
Figure 13.4  Prefilled Syringes Market for Anticoagulants, 2016-2026: Base Scenario (Million Units)
Figure 13.5  Prefilled Syringes Market for Anticoagulants, 2016-2026: Base Scenario (USD Million)
Figure 13.6  Prefilled Syringes Market for Anticoagulants, 2016: Distribution by Nature of Molecule (%)
Figure 13.7  Prefilled Syringes Market for Diabetes Drugs, 2016-2026: Base Scenario (Million Units)
Figure 13.8  Prefilled Syringes Market for Diabetes Drugs, 2016-2026: Base Scenario (USD Million)
Figure 13.9  Prefilled Syringes Market for Diabetes Drugs, 2016: Distribution by Nature of Molecule (%) 
Figure 13.10  Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016-2026: Base Scenario (Million Units)
Figure 13.11  Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016-2026: Base Scenario (USD Million)
Figure 13.12  Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016 and 2026: Distribution by Nature of Molecule (%)
Figure 13.13  Prefilled Syringes Market for Anti-Arthritic Drugs, 2016-2026: Base Scenario (Million Units)
Figure 13.14  Prefilled Syringes Market for Anti-Arthritic Drugs, 2016-2026: Base Scenario (USD Million)
Figure 13.15  Prefilled Syringes Market for Anti-Arthritic Drugs, 2016 and 2026: Distribution by Nature of Molecule (%)
Figure 13.16  Prefilled Syringes Market for Anti-Anemic Drugs, 2016-2026: Base Scenario (Million units)
Figure 13.17  Prefilled Syringes Market for Anti-Anemic Drugs, 2016-2026: Base Scenario (USD Million)
Figure 13.18  Prefilled Syringes Market for Anti-Anemic Drugs, 2016: Distribution by Nature of Molecule (%)
Figure 13.19  Prefilled Syringes Market for Other Drug Classes, 2016-2026: Base Scenario (Million Units)
Figure 13.20  Prefilled Syringes Market for Other Drug Classes, 2016-2026: Base Scenario (USD Million)
Figure 13.21  Prefilled Syringes Market for Other Drug Classes, 2016 and 2026: Distribution by Nature of Molecule (%)
Figure 13.22  Specialty Prefilled Syringes Market, 2016-2026: Base Scenario (Millions Units) 
Figure 13.23  Specialty Prefilled Syringes Market, 2016-2026: Base Scenario (USD Million)
Figure 13.24  Global Prefilled Syringes Market, 2016-2026: Base Scenario (Million Units)
Figure 13.25  Global Prefilled Syringes, Units Growth by Category, 2016-2026 (Base Scenario, Million Units)
Figure 13.26  Global Prefilled Syringes Market, 2016-2026: Base Scenario (USD Million)
Figure 13.27  Global Prefilled Syringes, Sales Growth by Category, 2016-2026 (Base Scenario, USD Million)
Figure 13.28  Prefilled Syringes Market: Distribution by Regions, 2016 and 2026 (%)
Figure 13.29  North America Prefilled Syringes Market, 2016-2026: Base Scenario (Million Units)
Figure 13.30  North America Prefilled Syringes Market, 2016-2026: Base Scenario (USD Million)
Figure 13.31  EU Prefilled Syringes Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (Million Units)
Figure 13.32  EU Prefilled Syringes Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (USD Million)
Figure 13.33  Asia Pacific Prefilled Syringes Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (Million Units)
Figure 13.34  Asia Pacific Prefilled Syringes Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (USD Million)
Figure 13.35  Latin America Prefilled Syringes Market, 2016 - 2026: Distribution by Sub-Regions, Base Scenario (Million Units)
Figure 13.36  Latin America Prefilled Syringes Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (USD Million)
Figure 13.37  Middle East and Africa Prefilled Syringes Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (Million Units)
Figure 13.38  Middle East and Africa Prefilled Syringes Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (USD Million)
Figure 13.39  Prefilled Syringes Market Attractiveness Analysis by Region
Figure 13.40  Prefilled Syringes Market, 2016-2026: Distribution by Type of Material, Base Scenario (Million Units)
Figure 13.41  Prefilled Syringes Market, 2016-2026: Distribution by Type of Material, Base Scenario (USD Million)
Figure 13.42  Prefilled Syringes Market, 2016-2026: Distribution by Nature of Molecule, Base Scenario (Million Units)
Figure 13.43  Prefilled Syringes Market, 2016-2026: Distribution by Nature of Molecule, Base Scenario (USD Million)
Figure 13.44  Prefilled Syringes Market Attractiveness Analysis by Nature of Molecule
Figure 14.1  Bespak Injectables: Autoinjectors
Figure 14.2  Bespak Injectables: Syrina™ Autoinjectors
Figure 14.3  DALI Medical Devices: Autoinjectors
Figure 14.4  Elcam Medical: Products
Figure 14.5  Elcam Medical: Flexi-Q Autoinjectors
Figure 14.6  Owen Mumford: Cartridge-Based Injection Pens
Figure 14.7  Owen Mumford: Autoinjectors
Figure 14.8  SHL Medical: Product Portfolio
Figure 14.9  SHL Medical:  Prefilled Syringe Based Autoinjectors
Figure 14.10  SHL Medical:  Cartridge Based Autoinjectors
Figure 14.11  SHL Medical: Two-Step Autoinjectors
Figure 14.12  SHL Medical: Three-Step Autoinjectors
Figure 14.13  Union Medico: 45˚ Autoinjector Portfolio
Figure 14.14  Union Medico: Types of 45˚/R Autoinjector
Figure 14.15  Union Medico: Types of 90˚ Autoinjectors
Figure 14.16  Ypsomed: Cartridge Based Pen injectors
Figure 14.17  Ypsomed: Cartridge Based Dual-Chamber Pen injectors
Figure 14.18  Ypsomed: Prefilled Syringe or Cartridge Based Autoinjectors
Figure 16.1  SWOT Analysis
Figure 16.2  Common Medication Errors
Figure 16.3  Common Sources of Medication Errors
Figure 16.4 Prefilled Syringe Recalls: Distribution by Type of Issue, 2003-2016
Figure 17.1  Fill and Finish Service Providers: Distribution by Region
Figure 17.2  Prefilled Syringes Market: 2016, 2021 and 2026 (Billion Units)
Figure 17.3  Prefilled Syringes Market: 2016, 2021, and 2026 (USD Billion)

List of Tables

Table 3.1  Drugs: Shifted from Vials to Prefilled Syringe Systems
Table 3.2  Components of Prefilled Syringes
Table 3.3  Classification of Prefilled Syringes
Table 3.4  Advantages of Glass as Barrel Material
Table 3.5  Prefilled Glass Syringe Recalls
Table 3.6  Advantages of Plastic Polymers as Barrel Material
Table 3.7  Pharmaceutical Filling Lines: Process Flow by Type of Prefilled Syringe
Table 3.8  Prefilled Syringe Systems Available in the Market, 2016: A Comparison by Manufacturer
Table 3.9  Glass Prefilled Syringes Available in the Market, 2016
Table 3.10  Plastic Prefilled Syringes Available in the Market, 2016
Table 4.1  Add-On Safety Device Manufacturers
Table 4.2  Integrated Prefilled Safety Device Manufacturers 
Table 5.1  USFDA Centers for Drugs and Device Approval
Table 5.2  US: Regulatory Review Timelines
Table 5.3  Regulatory Bodies in EU5 Countries
Table 5.4  Saudi Arabia: Regulatory Review Timelines
Table 6.1  Population above 60 years (Million), 2015, 2030 and 2050
Table 6.2  Autoinjector / Pen-injector Systems Approved in 2013-2016
Table 6.3  Autoinjectors / Pen-injectors (Using Prefilled Syringes) Available in the Market
Table 7.1  Drugs Approved in Prefilled Syringes, 2013-2016 
Table 7.2  Other Drugs Sold in Prefilled Syringes
Table 7.3  Pipeline Drugs Using Prefilled Syringe System 
Table 7.4  Leading Anti-Rheumatic Drugs 
Table 7.5  Anti-Rheumatics Drugs Available in Prefilled Syringes
Table 7.6  Anti-Rheumatic Drugs Available in Prefilled Format: Patent Expiry and Biosimilar Development
Table 7.7  Leading Multiple Sclerosis Drugs
Table 7.8  Multiple Sclerosis Drugs Available in Prefilled Syringes
Table 7.9  Multiple Sclerosis Drugs Available in Prefilled Format: Patent Expiry and Biosimilar Development
Table 7.10  Leading Antiviral Drugs
Table 7.11  Antiviral Drugs Available in Prefilled Syringes
Table 7.12  Antiviral Drugs Available in Prefilled Format: Patent Expiry and Biosimilar Development
Table 7.13  Leading Anticoagulants
Table 7.14  Anticoagulants Available in Prefilled Syringes
Table 7.15  Anticoagulants Available in Prefilled Format: Patent Expiry and Biosimilars /Generics Development
Table 7.16  Leading Vaccines
Table 7.17  Vaccines Available in Prefilled Syringes
Table 7.18  Leading Diabetes Drugs
Table 7.19  Diabetes Drugs Available in Prefilled Insulin Pen
Table 7.20  Diabetes Drugs Available in Prefilled Format: Patent Expiry and Biosimilar Development
Table 8.1  Marketed Molecules: Most Likely / Likely / Less likely Candidates for Prefilled Syringes
Table 8.2  Pipeline Molecules: Most Likely Candidates for Prefilled Syringes
Table 8.3  Pipeline Molecules: Likely Candidates for Prefilled Syringes
Table 8.4  Pipeline Molecules: Less Likely Candidates for Prefilled Syringes
Table 8.5  Vaccines: Likely Candidates for Prefilled Syringes
Table 9.1  Key Manufacturers of Prefilled Syringes
Table 9.2  West Pharmaceutical Services: Features of Daikyo Crystal Zenith® Prefilled Syringe
Table 9.3  Gerresheimer: Features of Gx® Glass Prefilled Syringe
Table 9.4  Gerresheimer: Features of ClearJect® Prefilled Syringe
Table 9.5  Nuova Ompi: Features of EZ-Fill® Prefilled Syringe
Table 9.6  SCHOTT: Features of syriQ® Prefilled Syringe
Table 9.7  SCHOTT: Features of syriQ® Injentle Prefilled Syringe
Table 9.8  SCHOTT: Features of TopPac® Prefilled Syringe
Table 9.9  Vetter Pharma: Manufacturing Facilities
Table 9.10  Weigao: Features of WeGo Glass Prefilled Syringe
Table 9.11  Roselabs Group: Features of Rose-Fill® Glass Prefilled Syringe
Table 9.12  Roselabs Group: Features of Rose-Fill® Plastic Prefilled Syringe
Table 9.13  Shandong Zibo: Features of Prefilled Syringes
Table 9.14  Taisei Kako: Features of Glass Prefilled Syringes
Table 9.15  Taisei Kako: Features of ClearJect®Prefilled Syringes
Table 10.1  Prefilled Syringe Component Manufacturers
Table 10.2  West Pharmaceutical Services: Plungers
Table 10.3  West Pharmaceutical Services: Manufacturing Sites for Prefilled Syringe Components
Table 10.4  Datwyler: Plunger Designs
Table 10.5  Datwyler: Needle Shields and Tip Caps
Table 10.6  Aptar Stelmi: Plungers Designs
Table 11.1  Fill-Finish Service Providers for Prefilled syringes 
Table 11.2  Pfizer CentreOne: Manufacturing Plants
Table 11.3  ROVI CM: Manufacturing Plants
Table 12.1  Prefilled Flush Syringes Available in the Market
Table 12.2  Drugs Available in Prefilled Diluent Syringe System 
Table 12.3  Contrast Agents Available in Prefilled Syringes 
Table 13.1  Prefilled Syringes Price Estimate (USD per unit)
Table 13.2  Vaccines Administered via Prefilled Syringes
Table 13.3  List of Anticoagulants and Mode of Delivery
Table 13.4  List of Anticoagulants Sold in Prefilled Syringes
Table 13.5  List of Multiple Sclerosis Drugs and Mode of Delivery
Table 13.6  List of Multiple Sclerosis Drugs Sold in Prefilled Syringes
Table 13.7  List of Anti-Arthritic Drugs and Mode of Delivery
Table 13.8  List of Anti-Arthritic Drugs Sold in Prefilled Syringes
Table 13.9  List of Anti-Anemic Drugs and Modes of Drug Delivery
Table 13.10  List of Anti-Anemic Drugs Sold in Prefilled Syringes
Table 13.11  List of Other Drugs Sold in Prefilled Syringes
Table 13.12  List of Marketed Drugs in Prefilled Syringes
Table 13.13  List of Pipeline Drugs in Prefilled syringes (Phase III and Above)
Table 14.1  List of Autoinjector Devices (Using Prefilled Syringes)
Table 14.2  Features of Autoject® Flex Variants
Table 15.1  Prefilled Syringes for Lyophilized Drugs
Table 15.2  Drugs Marketed in Dual / Multi-Chamber Prefilled Syringes
Table 16.1  Prefilled Syringe Recalls, 2003-2016
Table 16.2  List of Marketed/Pipeline Needleless Injection Devices
Table 19.1  Global Prevalence of Diabetes: Distribution by Countries, 2015 
(Million, %)
Table 19.2  Numbers of Biologics Approved by the USFDA, 2009-2016
Table 19.3  Approved Drugs: Therapeutic Area Analysis (2013-2016)
Table 19.4  Sales of Leading Drugs Available in Prefilled Syringes, 2016 (USD Million)
Table 19.5  HUMIRA®: Global Sales, 2003-Q3 2016 (USD Million)
Table 19.6  Enbrel®: Annual Sales in the US and Canada, 2002-2015 (USD Million)
Table 19.7  Enbrel®: Annual Sales Outside US and Canada, 2010-2015 (USD Million)
Table 19.8  Copaxone ®: Annual Sales, 2001-Q3 2016 (USD Million)
Table 19.9  Copaxone ®: Distribution by Vials and Prefilled Syringes, 2000-2008 (Million Units)
Table 19.10  Lovenox®: Global Annual Sales, 2009-Q3 2016 (EUR Million)
Table 19.11  Number of Approved / Pipeline Biosimilars of Anti-Rheumatics
Table 19.12  Number of Approved / Pipeline Biosimilars of Multiple Sclerosis Drugs
Table 19.13  Number of Approved / Pipeline Biosimilars of Antivirals
Table 19.14  Number of Approved / Pipeline Biosimilars and Generics of Anticoagulants
Table 19.15  Number of Approved / Pipeline Biosimilars of Diabetes Drugs
Table 19.16  BD Medical: Annual Revenues, 2011-2016 (USD Billion)
Table 19.17  BD Medical: Revenue Distribution by Sub-Segments, 2016 (USD Billion)
Table 19.18  Unilife Corporation: Annual Revenues, FY 2011/12-2015/16 (USD Million)
Table 19.19  West Pharmaceutical Services: Annual Revenues, 2011-Q3 2016 (USD Million)
Table 19.20  West Pharmaceutical Services: Revenue Distribution by Business Segments, 2015 (USD Million)
Table 19.21  West Pharmaceutical Services: Annual Revenues of Delivery Systems Segment, 2011-2015 (USD Million)
Table 19.22  West Pharmaceutical Services: Annual Revenue in the US and Overseas, 2011-2015 (USD Million)
Table 19.23  West Pharmaceutical Services: Revenue Distribution by Region, 2015 (USD Million)
Table 19.24  Gerresheimer: Annual Revenues, 2011-Q3 2016 (EUR Million)
Table 19.25  Gerresheimer: Revenue Distribution by Business Divisions, 2015 (EUR Million)
Table 19.26  Gerresheimer: Revenue Distribution by Regions, 2011- 2015 (EUR Million)
Table 19.27  SCHOTT: Annual Revenues, FY 2012/13-FY 2014/15 (EUR Million)
Table 19.28  SCHOTT: Revenue Distribution by Business Divisions, FY 2014/15 (EUR Million)
Table 19.29  SCHOTT: Revenue Distribution by Regions, FY 2014/15 (EUR Million)
Table 19.30  Nipro Corporation: Annual Revenues, 2011/12-2015/16 (YEN Billion)
Table 19.31  Nipro Corporation: Revenue Distribution by Business Divisions, 2015/16 (YEN Billion)
Table 19.32  Nipro Corporation: Revenue Distribution by Regions, 2015/16 (YEN Billion)
Table 19.33  Nipro Corporation: Revenue by Regions, 2011/12-2015/16 (YEN Billion)
Table 19.34  Weigao: Annual Revenues of Prefilled Syringes, 2011-H1 2016 (RMB Million)
Table 19.35  Weigao: Revenue Distribution by Product Category, 2015 (RMB Million)
Table 19.36  Terumo Corporation: Annual Revenues, 2011-H1 2016 (YEN Billion)
Table 19.37  Terumo Corporation: Revenue Distribution by Business Divisions, FY 2015/16 (YEN Billion)
Table 19.38  Terumo Corporation: Revenue Distribution by Region, FY 2015/16 (YEN Billion)
Table 19.39  Datwyler Group: Annual Revenues, 2011-H1 2016 (CHF Million)
Table 19.40  Datwyler Group: Sales by Business Divisions, 2015 (CHF Million)
Table 19.41  Aptar Stelmi: Annual Revenues, 2013-2015 (USD Million)
Table 19.42  Prefilled Syringes Price Curve, 2016-2026 (USD per unit)
Table 19.43  Prefilled Syringes Market for Vaccines, 2016-2026: Base Scenario (Million Units)
Table 19.44  Prefilled Syringes Market for Vaccines, 2016-2026: Optimistic Scenario (Million Units)
Table 19.45  Prefilled Syringes Market for Vaccines, 2016-2026: Conservative Scenario (Million Units)
Table 19.46  Prefilled Syringes Market for Vaccines, 2016-2026: Base Scenario (USD Million)
Table 19.47  Prefilled Syringes Market for Vaccines, 2016-2026: Optimistic Scenario (USD Million)
Table 19.48  Prefilled Syringes Market for Vaccines, 2016-2026: Conservative Scenario (USD Million)
Table 19.49  Prefilled Syringes Market for Anticoagulants, 2016-2026: Base Scenario (Million Units)
Table 19.50  Prefilled Syringes Market for Anticoagulants, 2016-2026: Optimistic Scenario (Million Units)
Table 19.51  Prefilled Syringes Market for Anticoagulants, 2016-2026: Conservative Scenario (Million Units)
Table 19.52  Prefilled Syringes Market for Anticoagulants, 2016-2026: Base Scenario (USD Million)
Table 19.53  Prefilled Syringes Market for Anticoagulants, 2016-2026: Optimistic Scenario (USD Million)
Table 19.54  Prefilled Syringes Market for Anticoagulants, 2016-2026: Conservative Scenario (USD Million)
Table 19.55  Prefilled Syringes Market for Anticoagulants, 2016: Distribution by Nature of Molecule (%)
Table 19.56  Prefilled Syringes Market for Diabetes Drugs, 2016-2026: Base Scenario (Million Units)
Table 19.57  Prefilled Syringes Market for Diabetes Drugs, 2016-2026: Optimistic Scenario (Million Units)
Table 19.58  Prefilled Syringes Market for Diabetes Drugs, 2016-2026: Conservative Scenario (Million Units)
Table 19.59  Prefilled Syringes Market for Diabetes Drugs, 2016-2026: Base Scenario (USD Million)
Table 19.60  Prefilled Syringes Market for Diabetes Drugs, 2016-2026: Optimistic Scenario (USD Million)
Table 19.61  Prefilled Syringes Market for Diabetes Drugs, 2016-2026: Conservative Scenario (USD Million)
Table 19.62  Prefilled Syringes Market for Diabetes Drugs, 2016: Distribution by Nature of Molecule (%)
Table 19.62  Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016-2026: Base Scenario (Million Units)
Table 19.63  Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016-2026: Optimistic Scenario (Million Units)
Table 19.64  Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016-2026: Conservative Scenario (Million Units)
Table 19.65  Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016-2026: Base Scenario (USD Million)
Table 19.66  Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016-2026: Optimistic Scenario (USD Million)
Table 19.67  Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016-2026: Conservative Scenario (USD Million)
Table 19.68  Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016 and 2026: Distribution by Nature of Molecule (%)
Table 19.69  Prefilled Syringes Market for Anti-Arthritic Drugs, 2016-2026: Base Scenario (Million Units)
Table 19.70  Prefilled Syringes Market for Anti-Arthritic Drugs, 2016-2026: Optimistic Scenario (Million Units)
Table 19.71  Prefilled Syringes Market for Anti-Arthritic Drugs, 2016-2026: Conservative Scenario (Million Units)
Table 19.72  Prefilled Syringes Market for Anti-Arthritic Drugs, 2016-2026: Base Scenario (USD Million)
Table 19.73  Prefilled Syringes Market for Anti-Arthritic Drugs, 2016-2026: Optimistic Scenario (USD Million)
Table 19.74  Prefilled Syringes Market for Anti-Arthritic Drugs, 2016-2026: Conservative Scenario (USD Million)
Table 19.75  Prefilled Syringes Market for Anti-Arthritic Drugs, 2016 and 2026: Distribution by Nature of Molecule (%)
Table 19.76  Prefilled Syringes Market for Anti-Anemic Drugs, 2016-2026: Base Scenario (Million Units)
Table 19.77  Prefilled Syringes Market for Anti-Anemic Drugs, 2016-2026: Optimistic Scenario (Million Units)
Table 19.78  Prefilled Syringes Market for Anti-Anemic Drugs, 2016-2026: Conservative Scenario (Million Units)
Table 19.79  Prefilled Syringes Market for Anti-Anemic Drugs, 2016-2026: Base Scenario (USD Million)
Table 19.80  Prefilled Syringes Market for Anti-Anemic Drugs, 2016-2026: Optimistic Scenario (USD Million)
Table 19.81  Prefilled Syringes Market for Anti-Anemic Drugs, 2016-2026: Conservative Scenario (USD Million)
Table 19.82  Prefilled Syringes Market for Anti-Arthritic Drugs, 2016: Distribution by Nature of Molecule (%)
Table 19.83  Prefilled Syringes Market for Other Drug Classes, 2016-2026: Base Scenario (Million Units)
Table 19.84  Prefilled Syringes Market for Other Drug Classes, 2016-2026: Optimistic Scenario (Million Units)
Table 19.85  Prefilled Syringes Market for Other Drug Classes, 2016-2026: Conservative Scenario (Million Units)
Table 19.86  Prefilled Syringes Market for Other Drug Classes, 2016-2026: Base Scenario (USD Million)
Table 19.87  Prefilled Syringes Market for Other Drug Classes, 2016-2026: Optimistic Scenario (USD Million)
Table 19.88  Prefilled Syringes Market for Other Drug Classes, 2016-2026: Conservative Scenario (USD Million)
Table 19.89  Prefilled Syringes Market for Other Drug Classes, 2016 and 2026: Distribution by Nature of Molecule (%)
Table 19.90  Specialty Prefilled Syringes Market, 2016-2026: Base Scenario (Millions Units)
Table 19.91  Specialty Prefilled Syringes Market, 2016-2026: Optimistic Scenario (Millions Units)
Table 19.92  Specialty Prefilled Syringes Market, 2016-2026: Conservative Scenario (Millions Units)
Table 19.93  Specialty Prefilled Syringes Market, 2016-2026: Base Scenario (USD Million)
Table 19.94  Specialty Prefilled Syringes Market, 2016-2026: Optimistic Scenario (USD Million)
Table 19.95  Specialty Prefilled Syringes Market, 2016-2026: Conservative Scenario (USD Million)
Table 19.96  Global Prefilled Syringes Market, 2016-2026: Base Scenario (Million Units)
Table 19.97  Global Prefilled Syringes Market, 2016-2026: Optimistic Scenario (Million Units)
Table 19.98  Global Prefilled Syringes Market, 2016-2026: Conservative Scenario (Million Units)
Table 19.99  Global Prefilled Syringes, Units Growth by Category, 2016- 026 (Base Scenario, Million Units)
Table 19.100  Global Prefilled Syringes, Units Growth by Category, 2016 - 2026 (Optimistic Scenario, Million Units)
Table 19.101  Global Prefilled Syringes, Units Growth by Category, 2016 - 2026 (Conservative Scenario, Million Units)
Table 19.102  Global Prefilled Syringes Market, 2016-2026: Base Scenario (USD Million)
Table 19.103  Global Prefilled Syringes Market, 2016-2026: Optimistic Scenario (USD Million)
Table 19.104  Global Prefilled Syringes, Sales Growth by Category, 2016-2026 (Conservative Scenario, USD Million)
Table 19.105  Global Prefilled Syringes, Sales Growth by Category, 2016-2026 (Base Scenario, USD Million)
Table 19.106  Global Prefilled Syringes, Sales Growth by Category, 2016-2026 (Optimistic Scenario, USD Million)
Table 19.107  Global Prefilled Syringes, Sales Growth by Category, 2016 - 2026 (Conservative Scenario, USD Million)
Table 19.108  Prefilled Syringe Market: Distribution by Regions, 2016 and 2026 (%)
Table 19.109  North America Prefilled Syringe Market, 2016-2026: Base Scenario (Million Units)
Table 19.110  North America Prefilled Syringe Market, 2016-2026: Optimistic Scenario (Million Units)
Table 19.111  North America Prefilled Syringe Market, 2016-2026: Conservative Scenario (Million Units)
Table 19.112  North America Prefilled Syringe Market, 2016-2026: Base Scenario (USD Million)
Table 19.113  North America Prefilled Syringe Market, 2016-2026: Optimistic Scenario (USD Million)
Table 19.114  North America Prefilled Syringe Market, 2016-2026: Conservative Scenario (USD Million)
Table 19.115  EU Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (Million Units)
Table 19.116  EU Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Optimistic Scenario (Million Units)
Table 19.117  EU Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Conservative Scenario (Million Units)
Table 19.118  EU Prefilled Syringe Market, 2016-2026: Base Scenario (USD Million)
Table 19.119  EU Prefilled Syringe Market, 2016-2026: Optimistic Scenario (USD Million)
Table 19.120  EU Prefilled Syringe Market, 2016-2026: Conservative Scenario (USD Million)
Table 19.121  Asia Pacific Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (Million Units)
Table 19.122  Asia Pacific Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Optimistic Scenario (Million Units)
Table 19.123  Asia Pacific Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Conservative Scenario (Million Units)
Table 19.124  Asia Pacific Prefilled Syringe Market, 2016-2026: Base Scenario (USD Million)
Table 19.125  Asia Pacific Prefilled Syringe Market, 2016-2026: Optimistic Scenario (USD Million)
Table 19.126  Asia Pacific Prefilled Syringe Market, 2016-2026: Conservative Scenario (USD Million)
Table 19.127  Latin America Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (Million Units)
Table 19.128  Latin America Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Optimistic Scenario (Million Units)
Table 19.129  Latin America Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Conservative Scenario (Million Units)
Table 19.130  Latin America Prefilled Syringe Market, 2016-2026: Base Scenario (USD Million)
Table 19.131  Latin America Prefilled Syringe Market, 2016-2026: Optimistic Scenario (USD Million)
Table 19.132  Latin America Prefilled Syringe Market, 2016-2026: Conservative Scenario (USD Million)
Table 19.133  Middle East and Africa Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (Million Units)
Table 19.134  Middle East and Africa Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Optimistic Scenario (Million Units)
Table 19.135  Middle East and Africa Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Conservative Scenario (Million Units)
Table 19.136  Middle East and Africa Prefilled Syringe Market, 2016-2026: Base Scenario (USD Million)
Table 19.137  Middle East and Africa Prefilled Syringe Market, 2016-2026: Optimistic Scenario (USD Million)
Table 19.138  Middle East and Africa Prefilled Syringe Market, 2016-2026: Conservative Scenario (USD Million)
Table 19.139  Prefilled Syringe Market Attractiveness Analysis by Region
Table 19.140  Prefilled Syringe Market, 2016-2026: Distribution by Type of Material, Base Scenario (Million Units)
Table 19.141  Prefilled Syringe Market, 2016-2026: Distribution by Type of Material, Optimistic Scenario (Million Units)
Table 19.142  Prefilled Syringe Market, 2016-2026: Distribution by Type of Material, Conservative Scenario (Million Units)
Table 19.143  Prefilled Syringe Market, 2016-2026: Distribution by Type of Material, Base Scenario (USD Million)
Table 19.144  Prefilled Syringe Market, 2016-2026: Distribution by Type of Material, Optimistic Scenario (USD Million)
Table 19.145  Prefilled Syringe Market, 2016-2026: Distribution by Type of Material, Conservative Scenario (USD Million)
Table 19.146  Prefilled Syringe Market, 2016-2026: Distribution by Nature of Molecule, Base Scenario (Million Units)
Table 19.147  Prefilled Syringe Market, 2016-2026: Distribution by Nature of Molecule, Optimistic Scenario (Million Units)
Table 19.148  Prefilled Syringe Market, 2016-2026: Distribution by Nature of Molecule, Conservative Scenario (Million Units)
Table 19.149  Prefilled Syringe Market, 2016-2026: Distribution by Nature of Molecule, Base Scenario (USD Million)
Table 19.150  Prefilled Syringe Market, 2016-2026: Distribution by Nature of Molecule, Optimistic Scenario (USD Million)
Table 19.151  Prefilled Syringe Market, 2016-2026: Distribution by Nature of Molecule, Conservative Scenario (USD Million)
Table 19.152  Prefilled Syringe Market Attractiveness Analysis by Nature of Molecules
Table 19.153  Common Medication Errors
Table 19.154  Common Sources of Medication Errors
Table 19.155  Prefilled Syringe Recalls: Distribution by Type of Issue, 2003-2016
Table 19.156  Prefilled Syringes Market: 2016, 2021 and 2026 (Billion Units)
Table 19.157  Prefilled Syringes Market: 2016, 2021, and 2026 (USD Billion)

Listed Companies

The following companies have been mentioned in the report.

  1. 3SBio
  2. Abbott 
  3. AbbVie Biotherapeutics
  4. AbbVie Contract Manufacturing
  5. Ablynx
  6. Acceleron Pharma
  7. Accord Healthcare
  8. AC Immune
  9. Activa Brand Products
  10. Adamis Pharmaceuticals Corporation
  11. Advanced Medical Systems
  12. AET BioTech
  13. Aeras
  14. Agila Biotech
  15. Aguettant
  16. AJ Biologics
  17. Ajinomoto Althea
  18. Akcea Therapeutics
  19. Akorn
  20. Aldagen 
  21. Alkermes
  22. Alteogen
  23. Adocia
  24. Alchemia 
  25. Alder BioPharmaceuticals
  26. Alfamatic
  27. Allergan
  28. Allergy Therapeutics
  29. Allozyne 
  30. Alkermes
  31. Almirall
  32. Alvogen
  33. AMEGA Biotech
  34. Amgen
  35. Amphastar Pharmaceuticals
  36. AnGes
  37. Antares Pharma
  38. Anthera Pharmaceuticals
  39. AOP Orphan Pharmaceuticals
  40. Apellis Pharmaceuticals
  41. APL Pharma
  42. Aptar Stelmi
  43. Apobiologix 
  44. Apotex
  45. Aquabiliti
  46. Araim Pharmaceuticals
  47. Argenx
  48. Ariston
  49. Arte Corporation
  50. AryoGen
  51. Aspen Group
  52. Astellas Pharma
  53. AstraZeneca
  54. Aurum Pharmaceuticals
  55. Avesthagen
  56. AXXO
  57. Bahrain Pharma
  58. Bang and Olufsen
  59. BASF Bioresearch Corporation
  60. Bavarian Nordic
  61. Baxter
  62. Bayer Healthcare
  63. B. Braun Medical
  64. Beacon Pharmaceuticals
  65. Becton Dickinson
  66. Bespak
  67. Bharat Serums & Vaccines
  68. BIOCAD
  69. Biocon
  70. BioConnection
  71. Bio Farma
  72. Biodel
  73. Bio Elpida
  74. BioGenomics
  75. BioIncept
  76. Bioject Medical Technologies
  77. BioMarin Pharmaceutical
  78. Bioneer
  79. BioPharma Solutions
  80. Biosidus
  81. Biotechpharma 
  82. Biotech Visioncare
  83. Bioviz Technologies
  84. BioXpress Therapeutics
  85. Blausiegel
  86. Blau Farmacêutica
  87. Boehringer Ingelheim BioXcellence
  88. Bone Therapeutics
  89. Boryung Pharmaceutical
  90. Bracco Diagnostics
  91. Braeburn Pharmaceuticals
  92. BrainStorm Cell Therapeutics
  93. Bristol Myers Squibb
  94. Bryllan
  95. Buender Glas
  96. Cadila Healthcare
  97. Cambridge Antibody Technology
  98. Cambridge Consultants
  99. Camurus
  100. Canyon Pharmaceuticals
  101. Capricor Therapeutics
  102. Cardinal Health
  103. Central Admixture Pharmacy Services
  104. Catalent Pharma Solutions
  105. CCM Pharmaceuticals
  106. Celgene
  107. Cellofarm
  108. Celltrion
  109. Cenexi
  110. Chandra Bhagat Pharma 
  111. Chugai Pharmaceutical 
  112. CinnaGen
  113. Cipla 
  114. Cipla BioTec
  115. Cobra Biologics
  116. Coherus Biosciences
  117. Consort Medical 
  118. Cook Pharmica
  119. Corden Pharma
  120. Covidien
  121. CP Guojian Pharmaceutical
  122. CROSSJECT
  123. Cytheris
  124. CytoDyn
  125. Cytori Therapeutics
  126. Credence MedSystems
  127. Crealta Pharmaceuticals
  128. CSL Biotherapies
  129. Daewoong Pharmaceutical
  130. Daicel Corporation
  131. Daiichi Sankyo
  132. Daikyo Seiko
  133. DALI Medical Devices
  134. Datwyler
  135. Dermira
  136. Diasome Pharmaceuticals
  137. Diamyd Medical
  138. DM Bio
  139. Dong-A Pharmaceutical
  140. Dr. Lazar Laboratorio
  141. Dr. Reddy's Laboratories
  142. Dynavax Technologies Corporation
  143. Eisai
  144. Elan Corporation
  145. Elcam Medical
  146. Eli Lilly
  147. Emcure Pharmaceuticals
  148. EMD Serono
  149. Emergent BioSolutions
  150. Enzon Pharmaceuticals
  151. Eternity Healthcare
  152. European Medical Contract Manufacturing 
  153. Eurofarma
  154. Evans Enterprises
  155. EVER Pharma
  156. Excelsior Medical
  157. Exsulin
  158. Eyetech 
  159. Farmabion Del Ecuador
  160. Ferring Pharmaceuticals
  161. Finox Biotech 
  162. Flamel Technologies
  163. Fresenius Kabi
  164. Fujifilm Kyowa Kirin Biologics
  165. Future Injection Technologies
  166. Gan & Lee Pharmaceutical
  167. Gedeon Richter
  168. GE Healthcare
  169. Genentech
  170. GeneOne Life Sciences
  171. Gene Techno Science
  172. Genovior Biotech 
  173. Generon (Shanghai) Corporation
  174. Genocea Biosciences
  175. Genzyme Corporation
  176. GeoVax
  177. Gerresheimer
  178. GeroPharm
  179. Gerot Lannach Pharma 
  180. Gilead Sciences
  181. Gland Pharma
  182. GlaxoSmithKline
  183. GlobeImmune
  184. Globe Medical Tech
  185. Green Cross Corporation
  186. Guerbet
  187. Halozyme Therapeutics
  188. HanAll Biopharma
  189. Hanmi Pharmaceutical
  190. Hanwha Chemical
  191. Harvest Moon Pharmaceuticals 
  192. Haselmeier
  193. Health for personal care corporation
  194. Helocyte
  195. Helvoet Pharmaceutical
  196. Hemispherx Bioscience
  197. Heron Therapeutics
  198. Hikma Pharmaceuticals
  199. Hospira
  200. Horizon Pharma
  201. Hyaluron Contract Manufacturing
  202. Ichor Medical Systems
  203. ID Biomedical Corporation of Quebec
  204. Idera Pharmaceutical
  205. Il-Yang Pharm
  206. Immunex Corporation
  207. Immunomedics
  208. Immune Response BioPharma
  209. Incepta Pharmaceuticals
  210. Indivior
  211. Infusive Technologies
  212. Injex
  213. Inovio Pharmaceuticals
  214. Innovate UK
  215. Intas Pharmaceuticals
  216. Intarcia Therapeutics
  217. Integrated BioTherapeutics
  218. Integrity Bio
  219. Ionis Pharmaceuticals
  220. Ipsen
  221. Italfarmaco
  222. IVEK Corporation
  223. Johnson & Johnson
  224. J.O. Pharma 
  225. JSR Corporation
  226. JCR Pharmaceuticals
  227. JMS
  228. JN-International Medical Corporation
  229. Juventas Therapeutics
  230. Kaleo
  231. Kastle Therapeutics
  232. Kendall
  233. Kineta
  234. Kitasato Daiichi Sankyo Vaccine
  235. Kyowa Hakko Kirin
  236. Laboratorios SALVAT 
  237. Landec Corporation
  238. Landsteiner Laboratories
  239. LEO Pharma
  240. LG Life Sciences
  241. Liebmann Group
  242. Lifecore Biomedical 
  243. Lundbeck
  244. Lupin Pharmaceuticals
  245. LyoGo
  246. Mada Equipment
  247. Mallinckrodt
  248. Marathon Pharmaceuticals
  249. Maruishi Pharmaceutical
  250. Medac Pharma
  251. Medefil
  252. Medex
  253. Medicago
  254. MedicalChain International Corporation
  255. Medical Glass
  256. MedImmune
  257. Medimop Medical Projects
  258. MedPro Safety Products
  259. Medtronic
  260. MedXL
  261. Meiji Seika Pharma
  262. Merck
  263. Meridian Medical Technologies
  264. Merz Pharma
  265. MGlas
  266. Minapharm Pharmaceuticals
  267. Mitsubishi Tanabe
  268. Mitsui Chemicals
  269. Mitsubishi Gas Chemical
  270. MJ Biopharm
  271. Mochida Pharmaceuticals
  272. Momenta Pharmaceuticals
  273. Mycenax Biotech
  274. Mylan Institutional
  275. Nanogen Biopharmaceutical
  276. Nanotherapeutics
  277. NATCO Pharma
  278. National Medical Products 
  279. Nektar Therapeutics
  280. Nemera
  281. Neon Laboratories
  282. Neutral Glass & Allied industries
  283. Nippon Organon
  284. Nipro Corporation
  285. Nora Therapeutics
  286. Novartis
  287. Novalek Pharmaceuticals 
  288. Nova Laboratories
  289. NovaDigm Therapeutics
  290. Novavax
  291. Novo Nordisk
  292. Noxilizer
  293. NPS Pharmaceuticals
  294. Nuance Designs
  295. Nuova Ompi
  296. Nuron Biotech
  297. Nurse Assist
  298. Okairos
  299. Omnikron Group
  300. Oncobiologics
  301. Ono Pharmaceutical
  302. Opexa Therapeutics
  303. OPKO Biologics
  304. Optimum Medical
  305. OrbiMed
  306. Otsuka Holdings
  307. Oval Medical Technologies
  308. Owen Mumford
  309. PA Consulting
  310. Palatin Technologies
  311. PANPHARMA
  312. Paras Biopharmaceuticals
  313. Pars No Tarkib
  314. PenJect
  315. Pfenex
  316. Pfizer
  317. Pfizer CentreOne
  318. PharmaEssentia Corporation
  319. Pharmicell
  320. Pharmathen
  321. PhaseBio Pharmaceuticals
  322. PiSA Farmaceutica
  323. Plas-Tech Engineering
  324. Pluristem Therapeutics
  325. Polpharma
  326. Polyplastics
  327. PROBIOMED
  328. Profectus BioSciences
  329. ProJect  Pharmaceutics
  330. Protalix BioTherapeutics
  331. Protein Sciences Corporation
  332. PT Bio Farma
  333. PYRAMID Laboratories
  334. Radius Health
  335. Ranbaxy Laboratories
  336. Regeneron Pharmaceuticals
  337. Reliance Life Sciences
  338. REMD Biotherapeutics
  339. Retractable Technologies
  340. Revolutions Medical Corporation
  341. Rexam Pharma
  342. Rhône Poulenc-Rorer
  343. Rheim Minapharm
  344. Rhythm Pharmaceuticals
  345. Rompharm Company
  346. Roselabs Bioscience
  347. Rovi CM
  348. SafeShot Technologies
  349. Safety Syringes
  350. Samsung Bioepsis
  351. Sandoz
  352. Sanofi Aventis
  353. Sanofi Pasteur
  354. Santarus
  355. Schering-Plough
  356. Schreiner MediPharm
  357. SCHOTT
  358. SHOTT KAISHA
  359. Sciele Pharma
  360. Seqirus
  361. Shandong Pharmaceutical Glass
  362. Shandong Weigao Group Medical Polymer Company
  363. Shandong Zibo Minkang Pharmaceutical Packing
  364. Shanghai Celgen Bio-Pharmaceutical
  365. Shantha Biotech
  366. Shin Yan Sheno Precision Industrial
  367. Shire
  368. SHL Medical
  369. SiO2 Medical Products
  370. Sobi
  371. Soligenix
  372. Solvay Pharmaceuticals
  373. SOVEREIGN PHARMA
  374. Spectrum Pharmaceuticals
  375. STADA Arzneimittel
  376. Stevanato Group
  377. Stiefel 
  378. Strides
  379. Sumagen
  380. Sun Pharmaceutical Industries
  381. Sunshine Health Products
  382. Suzuken 
  383. Swissfillon
  384. TaiMed Biologics
  385. Taisei Kako
  386. Taiyo Yakuhin
  387. Taj Pharmaceuticals
  388. Takeda Pharmaceutical 
  389. Talecris Biotherapeutics
  390. Techno Pharm
  391. Techdow Pharmaceuticals
  392. Teijin Pharma
  393. Terumo Corporation
  394. Teva Pharmaceuticals
  395. The Birgi Mefar Group
  396. The Medical House
  397. The Medicines Company
  398. Therapure Biopharma
  399. The Tech Group 
  400. Ticona
  401. Tip-Top
  402. TOLMAR
  403. TriboFilm Research
  404. Triveni Polymers 
  405. Troikaa Pharmaceuticals
  406. TSH Biopharm Corporation
  407. Tyfill Pharmapack
  408. UCB
  409. Unicep
  410. Unilife Corporation
  411. Unimed del Perú
  412. Union Medico
  413. United Neuroscience
  414. United Therapeutics
  415. U.S. Medical Instruments
  416. Valeant Pharmaceutical International
  417. Valeritas
  418. Vedat 
  419. Vaneva
  420. VaxInnate
  421. Versartis
  422. Vetter Pharma
  423. ViaCyte
  424. Vical
  425. Vitaeris
  426. Virchow Biotech 
  427. Viropro
  428. ViroMed
  429. Watson Pharma
  430. WestCon Medical Industries
  431. West Pharmaceutical Services
  432. Weigao Group Pharmaceutical Packaging Products
  433. Wockhardt
  434. Wyeth
  435. XBiotech
  436. Xbrane Biopharma
  437. XOMA
  438. YangZhong Wealth Metal
  439. Youlyy Industrial 
  440. Ypsomed Delivery Systems
  441. Zealand Pharma
  442. Zeon Chemicals
  443. Zensun 
  444. Zhejiang Hisun Pharmaceutical
  445. Zhejiang Huahai Pharmaceutical
  446. Zhejiang Xinkang Pharmaceutical Glass
  447. Zogenix
  448. Zydus Cadila
  449. ZymoGenetics

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 2,349

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com